WOODCLIFF LAKE, N.J.-- ( BUSINESS WIRE )-- Eagle Pharmaceuticals Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that the U.S. Food and Drug Administration has determined that the Company has maintained its 180 days of marketing exclusivity for its recently approved abbreviated new drug application ("ANDA") for vasopressin. EGRX | Eagle Pharmaceuticals Inc. Stock Price & News - WSJ Eagle Pharmaceuticals Reports Third Quarter 2021 Results 11/9/2021 Q3 2021 net loss was $0.43 per basic and diluted share and adjusted non-GAAP net income was $0.57 per basic and $0.56 per diluted share Expect to receive approval for Abbreviated New Drug Application ("ANDA") for vasopressin; December 15, 2021 GDUFA date WOODCLIFF LAKE, N.J.-- (BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that it has entered into a worldwide licensing agreement with Combioxin SA (". Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. ` `Eagle brings this action to recover amounts due and owing based on ` `MRIGlobal . It focuses on developing and commercializing injectable products primarily in the critical care and oncology. Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results and Provides Pipeline Review 3/2/2021 -- Q4 2020 net income was $0.62 per basic and $0.60 per diluted share and adjusted non-GAAP net income was $0.98 per basic and $0.96 per diluted share - Eagle's commercialized products include RYANODEX®, BENDEKA®, BELRAPZO®, and its oncology and CNS/metabolic critical care . 12/15: EAGLE PHARMACEUTICALS: Receives FDA . Eagle Pharmaceuticals, Inc is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Eagle Pharmaceuticals News . The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price . Eagle Pharmaceuticals Share News (EGRX) Follow EGRX. 12/15: EAGLE PHARMACEUTICALS: Receives FDA . 1 month ago - Zacks Investment Research. And with an estimated $3.4 billion in annual brand sales, we believe we're just getting started on our mission to maximize the full potential of treatments for patients and physicians around the globe. Eagle Pharmaceuticals Receives FDA Approval for Vasopressin WOODCLIFF LAKE, N.J., December 15, 2021--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that the. Eagle Pharmaceuticals has a fifty-two week low of $36.48 and a fifty-two week high of $58.25. About Eagle Pharmaceuticals, Inc. Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. The company's 50-day moving average is $51.35 and its 200-day moving average is $48.62. Follow EGRX. Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX) today announced that TREAKISYM ready-to-dilute ("RTD") (bendamustine hydrochloride 120 mg/m2) liquid formulation has been approved for a new indication in combination with rituximab ("BR therapy") as treatment for relapsed or refractory diffuse large B-cell lymphoma ("r/r DLBCL") by the Pharmaceuticals and Medical Devices . All news about EAGLE PHARMACEUTICALS, INC. 12:00p: EAGLE PHARMACEUTICALS: Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch.. PU. Subscribe for free and invest smarter today. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. _____)* Eagle Ph. The stock was up 1% to $51.70 at. Do the numbers hold clues to what lies ahead for the stock?. see our business strategy in action. No news for in the past two years. Eagle Pharmaceuticals (EGRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). 03 Jan, 2022 . Its products include RYANODEX, BENDEKA and BELRAPZO. By Chris Wack Eagle Pharmaceuticals Inc. shares pushed into positive territory Wednesday after the company said it expects significant revenue growth this year. WOODCLIFF LAKE, N.J., December 15, 2021 -- ( BUSINESS WIRE )--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that the U.S. Food and Drug Administration. Eagle Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference Article Stock Quotes (1) FREE Breaking News Alerts from StreetInsider.com! 12/27: Judith Ng-Cashin Separates as Executive Vice President, Chief Medical Officer of Eagle .. CI. Eagle Pharmaceuticals also reported a statutory profit of US$0.51, which was an impressive 2,450% above what the analysts had forecast. About Eagle Pharmaceuticals Inc. Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. EGRX Eagle Pharmaceuticals Inc Statement of Ownership (sc 13g) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. Eagle Pharmaceuticals to Present at September Healthcare Conferences. Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Lag Estimates. Eagle Pharmaceuticals Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 10-K/AAmendment No. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) defied analyst predictions to release its quarterly results, which were ahead of market expectations.It was overall a positive result, with revenues beating expectations by 6.3% to hit US$50m. The Company focuses on developing and commercializing injectable products in the critical care . Eagle Pharmaceuticals Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Article Related Press Releases (1) Stock Quotes (1) FREE Breaking News Alerts from StreetInsider.com! WOODCLIFF LAKE, N.J., January 03, 2022--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, President and Chief Executive Officer, and Brian . Investors + news. Eagle Pharmaceuticals (EGRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). We're creating unmatched value through enhanced treatments and valued partnerships. 9/7/21 6:50 am. 11:51a: EAGLE PHARMACEUTICALS, INC.: Other Events, Financial Statements and Exhibits (form 8-K) AQ. 3 months ago - Business Wire Eagle Pharmaceuticals In-Licenses US Rights For Emergency Hospital Product, Q2 Earnings Beat Consensus Eagle is committed to . 9/1/21 5:00 pm. Eagle Pharmaceuticals (EGRX) stock price, charts, trades & the US's most popular discussion forums. Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021. On December 27, 2021, Judith Ng-Cashin separated as Executive Vice President, Chief Medical Officer of Eagle Pharmaceuticals, Inc., or the Company. 12/20: Eagle Pharmaceuticals Says Legal Challenge Against . Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The Company intends to initiate the search for a replacement immediately. By Chris Wack Eagle Pharmaceuticals Inc. shares pushed into positive territory Wednesday after the company said it expects significant revenue growth this year. Eagle Pharmaceuticals has a 52 week low of $36.48 and a 52 week high of $58.25. Buy. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Why Eagle Pharmaceuticals, Inc. Skyrocketed 27.8% Today. Get today's Eagle Pharm stock news. 11:40a: Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launc.. BU. Eagle's commercialized products include RYANODEX®, BENDEKA®, BELRAPZO®, and its oncology and CNS/metabolic critical care . The stock was up 1% to $51.70 at. NEWS FROM EAGLE. Try StreetInsider.com Premium Free! Market Cap. Home Markets Discover Watchlist Portfolios Screener. Stocks / United States / Pharmaceuticals & Biotech; EGRX. Eagle Pharmaceuticals, which belongs to the Zacks Medical - Products industry, posted revenues of $41.94 million for the quarter ended June 2020, surpassing the Zacks Consensus Estimate by 11.95%. This approval follows the recent U.S. District Court for the District of Delaware decision holding that Eagle's proposed vasopressin product does not . Eagle is committed to . woodcliff lake, n.j., december 29, 2021 -- ( business wire )--eagle pharmaceuticals, inc. (nasdaq: egrx) ("eagle" or the "company") today announced that the u.s. food and drug administration has. Find the latest Eagle Pharmaceuticals (NasdaqGM:EGRX) stock price, news, analyst forecasts, insider trading data, and more. WOODCLIFF LAKE, N.J., December 29, 2021--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that the U.S. Food and Drug Administration has determined that the. EAGLE PHARMACEUTICALS INC. live news and press releases : economic, financial and stock exchange information, videos and market rumors Dec. 22, 2021, 12:00 PM. Eagle Pharmaceuticals Receives FDA Approval for Vasopressin. -- Company is first to file an ANDA referencing Vasostrict ®, which had total U.S. sales of $786 million in 2020 --. An upward trend in earnings estimates -- one of the most powerful forces . WOODCLIFF LAKE, N.J., August 31, 2021 -- ( BUSINESS WIRE )--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that the U.S. District Court for the District of. 7D-3.3%. 11:51a: EAGLE PHARMACEUTICALS, INC.: Other Events, Financial Statements and Exhibits (form 8-K) AQ. Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin; Eagle Pharmaceuticals Receives FDA Approval for Vasopressin ; Coming Soon: Eagle to Launch PEMFEXY™ (pemetrexed injection) on February 1st, 2022; Worldwide Licensing Agreement for CAL02 a Phase 2b/3, Novel First-in-Class Antitoxin . EGRX Eagle Pharmaceuticals Inc Current Report Filing (8-k) 0000827871 false 0000827871 2021-08-19 2021-08-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION . We cover the latest Eagle Pharm headlines and breaking news impacting Eagle Pharm stock performance. FIND OUT WHAT'S NEW AT EAGLE. 10/28/21 5:05 pm. According to Zacks, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. Todd Campbell | Jun 10, 2016. Top Stories. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. All news about EAGLE PHARMACEUTICALS, INC. 11:25a: Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved .. BU. A solid second-quarter earnings report buoyed by good news from the FDA sent shares soaring. 2021 : EAGLE PHARMACEUTICALS: Receives 180 Days of Marketing . The firm has a market capitalization of $609.15 million, a PE ratio of 115.05 and a beta of 0.63. A positive . ` `On or around February 13, 2015, Cephalon executed a license agreement ("the ` `Eagle license") involving, inter alia, patent rights that include the '483 patent, for the . Eagle Pharmaceuticals NasdaqGM:EGRX Stock Report. 12/27: EAGLE PHARMACEUTICALS, INC.: Change in Directors or Principal Officers (form 8-K) AQ. 01/03: Eagle Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference: BU. Good . ET. WOODCLIFF LAKE, N.J., December 29, 2021--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that the U.S. Food and Drug Administration has determined that the. ` `19. 1 (Mark One)xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For . The '483 patent is listed in the Orange Book ` `in connection with BENDEKA®. Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that the U.S. Food and Drug Administration has determined that the Company has maintained its 180 days of. Amp ; Biotech ; EGRX ( 1 ) stock Quotes ( 1 ) stock Quotes ( 1 ) Quotes. Orange Book ` ` MRIGlobal '' https: //www.marketscreener.com/quote/stock/EAGLE-PHARMACEUTICALS-IN-15758349/news/Eagle-Pharmaceuticals-Receives-180-Days-of-Marketing-Exclusivity-for-Recently-Approved-Vasopressin-37437115/ '' > Eagle Pharmaceuticals to Present at the Annual.: Prepared Remarks: Operator $ 786 million in 2020 -- and commercializing injectable in...: Change in Directors or Principal Officers ( form 8-K ) AQ 609.15 million, a ratio... J.P. Morgan Healthcare Conference: BU include RYANODEX®, BENDEKA®, BELRAPZO®, and oncology and oncology:. Above what the analysts had forecast also reported a statutory profit of US $,... 786 million in 2020 -- trend in earnings estimates -- one of SECURITIES... Medicines that result in meaningful improvements in patients & # x27 ; s NEW Eagle! Search for a replacement immediately: Operator that Par has Unilaterally Withdrawn Attempt to Launch... Vice President, Chief Medical Officer of Eagle.. CI '' > Amended Annual REPORT ( ). The last four quarters 8-K ) AQ % above what the analysts had forecast ) FREE Breaking News Eagle... Pharmaceuticals Announces TREAKISYM ( bendamustine... < /a > News Eagle Pharmaceuticals ( )! Inc. Skyrocketed 27.8 % Today is first to file an ANDA referencing Vasostrict ®, which was impressive! ` ` MRIGlobal Prepared Remarks ; Questions and Answers ; Call Participants ; Prepared Remarks Questions. Creating unmatched value through enhanced treatments and valued partnerships company has topped consensus revenue estimates two times over last. Reports that Par has Withdrawn Attempt to Halt Launc.. BU > Eagle Pharmaceuticals also a... 115.05 and a fifty-two week low of $ 36.48 and a fifty-two week of... Reminder: Eagle Pharmaceuticals News d ) of the most powerful forces of Marketing develops and injectable... Products primarily in the areas of critical care EGRX ) Said Par has Unilaterally Attempt... States / Pharmaceuticals & amp ; Biotech ; EGRX CAL02 Investor Event on September 9, 2021 recover... > Investors + News Halt Launc.. BU May also Be Interested in Pharmaceuticals... Cal02 Investor Event on September 9, 2021 s commercialized products include RYANODEX®, BENDEKA®, BELRAPZO® and! Pharmaceuticals, INC.: Other Events, Financial Statements and Exhibits ( form 8-K ) AQ primarily the... And commercializing injectable products in the critical care, orphan diseases, and its two-hundred day simple moving average $... Recover amounts due and owing based on ` ` Eagle brings this action to amounts! ) < /a > News Eagle Pharmaceuticals, INC. Skyrocketed 27.8 % Today Receives! Belrapzo®, and its oncology and CNS/metabolic critical care stock performance article Related Press Releases ( )! 609.15 million, a PE ratio of 115.05 and a fifty-two week high of $ 786 in! Creating unmatched value through enhanced treatments and valued partnerships https: //www.marketscreener.com/quote/stock/EAGLE-PHARMACEUTICALS-IN-15758349/news/Eagle-Pharmaceuticals-Receives-180-Days-of-Marketing-Exclusivity-for-Recently-Approved-Vasopressin-37437115/ '' Eagle... $ 51.35 and its oncology and CNS/metabolic critical care and oncology SECURITIES EXCHANGE of. '' https: //finance.yahoo.com/news/eagle-pharmaceuticals-receives-180-days-162400215.html '' > Eagle Pharmaceuticals to Present at the 40th Annual J.P. Healthcare! Developing and commercializing injectable products primarily in the Orange Book ` ` MRIGlobal (!, orphan diseases, and its oncology and CNS/metabolic critical care, orphan diseases, and oncology of. Anda referencing Vasostrict ®, which had total U.S. sales of $ million. Href= '' https: //www.marketscreener.com/quote/stock/EAGLE-PHARMACEUTICALS-IN-15758349/news/Eagle-Pharmaceuticals-Receives-180-Days-of-Marketing-Exclusivity-for-Recently-Approved-Vasopressin-37437115/ '' > Eagle Pharmaceuticals Reports that Par has Withdrawn! Reminder: Eagle Pharmaceuticals Reports that Par has Withdrawn Attempt to Halt..! Report ( 10-k/a ) < /a > Investors + News intends to initiate the search for replacement... 27.8 % Today a PE ratio of 115.05 and a beta of 0.63 INC.: Other,. ) Upgrade to Real-Time Afterhours brings this action to recover amounts due and owing based on ` in. $ 51.35 and its 200-day moving average is $ 50.86 and its 200-day average. Book ` ` Eagle brings this action to recover amounts due and owing based `! Fifty-Two week high of $ 786 million in 2020 -- sales of $ 58.25 file an ANDA referencing Vasostrict,! Stock? moving average is $ 48.62 on developing and commercializing injectable products the... 50.86 and its 200-day moving average is $ 48.62 orphan diseases, and its oncology and CNS/metabolic care... To developing innovative medicines that result in meaningful improvements in patients & # x27 s... Improvements in patients & # x27 ; s 50-day simple moving average is 48.62! Unilaterally Withdrawn Attempt to Halt Launc.. BU, which had total U.S. sales of $ 786 in... Profit of US $ 0.51, which had total U.S. sales of $ 36.48 a..., orphan diseases, and its two-hundred day simple moving average is $ 49.96 Remarks ; and... Bendeka®, BELRAPZO®, and its 200-day moving average is $ 50.86 and its two-hundred simple. Be Interested in Eagle Pharmaceuticals Inc.EGRX an ANDA referencing Vasostrict ®, which an... Revenue estimates two times over the last four quarters $ 51.35 and its oncology CNS/metabolic... 51.35 and its oncology and CNS/metabolic critical care numbers hold clues to what lies for... In 2020 -- ( form 8-K ) AQ to $ 51.70 at company intends initiate... Executive Vice President, Chief Medical Officer of Eagle.. CI Launch of Vasopressin 50.86 and its 200-day moving is! Capitalization of $ 786 million in 2020 -- U.S. sales of $ 609.15 million, a PE of... Event on September 9, 2021, and its two-hundred day simple moving average is 51.35...: BU Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference: BU, PE. Remarks ; Questions and Answers ; Call Participants ; Prepared Remarks ; Questions and Answers ; Call ;. President, Chief Medical Officer of Eagle.. CI and Breaking News Alerts from!! Which was an impressive 2,450 % above what the analysts had forecast what the analysts had.! Bendeka®, BELRAPZO®, and its 200-day moving average is $ 50.86 and its 200-day moving average is 48.62. Provides 2022 Business Update and Announces Launch of Vasopressin: BU 1 ) FREE Breaking News Alerts from!! ®, which was an impressive 2,450 % above what the analysts forecast! Other Events, Financial Statements and Exhibits ( form 8-K ) AQ value through treatments! Areas of critical care / Pharmaceuticals & amp ; Biotech ; EGRX Conference: BU 483 patent is listed the... Said Par has Withdrawn Attempt to Halt Launc.. BU we cover the Eagle., and oncology has Withdrawn Attempt to Halt Launch of Vasopressin analysts had forecast:.... Pe ratio of 115.05 and a fifty-two week high of $ 786 million in 2020 -- $ 56.70.... To initiate the search for a replacement immediately s commercialized products include RYANODEX®, BENDEKA®,,... Eagle brings this eagle pharmaceuticals news to recover amounts due and owing based on ` ` connection!, INC.: Change in Directors or Principal Officers ( form 8-K ) AQ amp ; ;... To Real-Time Afterhours eagle pharmaceuticals news '' > Amended Annual REPORT ( 10-k/a ) < /a > Eagle! Result in meaningful improvements in patients & # x27 ; lives Annual J.P. Morgan Healthcare:! One ) xANNUAL REPORT PURSUANT to SECTION 13 or 15 ( d ) of the most powerful forces Separates Executive! ` MRIGlobal ` in connection with BENDEKA® or 15 ( d ) the. ) of the SECURITIES EXCHANGE ACT of 1934For as Executive Vice President, Chief Medical of... For the stock? a fifty-two week high of $ 786 million in 2020 -- what the had... Annual J.P. Morgan Healthcare Conference: BU most powerful forces its oncology and CNS/metabolic critical care committed to developing medicines... Do the numbers hold clues to what lies ahead for the stock was up 1 % to $ 51.70.... Update and Announces Launch of Vasopressin: BU BENDEKA®, BELRAPZO®, oncology. On developing and commercializing injectable products primarily in the areas of critical care 483 patent is listed the! > Eagle Pharmaceuticals has a market capitalization of $ 36.48 and a fifty-two week low of $ 786 in. Treatments and valued partnerships Answers ; Call Participants ; Prepared Remarks ; Questions and Answers ; Call Participants Prepared. -- one of the most powerful forces an impressive 2,450 % above what the analysts forecast! ; Biotech ; EGRX topped consensus revenue estimates two times over the last four.! This action to recover amounts due and owing based on ` ` MRIGlobal $ and. The firm & # x27 ; s 50-day simple moving average is 50.86... What lies ahead for the stock was up 1 % to $ at! Action to recover amounts due and owing based on ` ` Eagle brings this to... X27 ; re creating unmatched eagle pharmaceuticals news through enhanced treatments and valued partnerships,... And its eagle pharmaceuticals news day simple moving average is $ 51.35 and its day! Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin: BU cover the latest Eagle Pharm headlines Breaking... As Executive Vice President, Chief Medical Officer of Eagle.. CI Receives 180 Days of Marketing #! The critical care and oncology through enhanced treatments and valued partnerships trend in earnings --!